Agilent Technologies Inc. (A) Wednesday said that its MMR IHC Panel pharmDx, developed in partnership with Bristol Myers Squibb, has received approval from the U.S.Food and Drug Administration (FDA) as a companion diagnostic test for colorectal cancer.
This test helps to identify mismatch repair deficient colorectal cancer patients who are eligible for treatment with Bristol Myers Squibb's Opdivo alone or in combination with Yervoy.
"Our new CDx product offers healthcare providers an additional tool to identify mismatch repair deficiency in patients, complementing existing options and enhancing the ability to tailor immunotherapy treatments," said Nina Green, vice-president and general manager of Agilent's Clinical Diagnostics Division.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.